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Abstract
Antimicrobial stewardship programmes promote excellence in the use of antimicrobials by selecting the appropriate antimicrobial agent
and the correct dose, route of administration and duration of treatment. However, there is limited experience with such programmes
targeting antifungal treatments. We present the results of a non-compulsory programme for the control of antifungals. For 12 months,
prescriptions of oral voriconazole or intravenous voriconazole, caspofungin and liposomal amphotericin B were reviewed, and non-com-
pulsory recommendations were made. The incidence and outcome of fungal infections were examined. The results for the dispensed
deﬁned daily doses (DDDs) and expenditure on antifungals were compared with those for the previous 12 months. The number of anti-
fungal treatments reviewed was 662. A recommendation to change treatment was made in 29% of the cases, including a change from
intravenous to oral treatment (15%), cessation of antifungal treatment (8%), and a change to ﬂuconazole (6%). The DDDs of intrave-
nous voriconazole and caspofungin were reduced by 31.4% and 20.2%, respectively. The DDDs of oral voriconazole and dispensed vials
of liposomal amphotericin B were increased by 8.2% and 13.9%, respectively. Expenditure on antifungals was reduced by US$370681.78
(11.8% reduction). The programme was not related to signiﬁcant increases in the incidence of candidaemia, percentage of persistent/
relapsing candidaemia cases, percentage of ﬂuconazole-resistant Candida species, incidence of infections by ﬁlamentous fungi, or 12-
month mortality in patients with ﬁlamentous fungal infections. In conclusion, a stewardship programme targeting antifungals achieved a
reduction in antifungal expenditure without reducing the quality of care provided.
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Introduction
Inappropriate use of antifungals contributes to the global
increase in antifungal resistance, and may lead to a variety of
adverse outcomes, including unnecessary exposure to drugs
and increased costs [1,2]. The prompt initiation of effective
antifungal therapy reduces patient mortality. However, the
indiscriminate application of risk factor-based prediction
models leads to a massive increase in the number of unnec-
essarily treated patients [3]. New antifungals have slight dif-
ferences in the spectrum of action, dose required, route of
administration, and interactions with other drugs, which are
difﬁcult to manage by a non-fungal specialist [3]. Therefore,
the need for stewardship programmes targeting antifungals
has been raised [3,4].
Methods
Setting
The study was developed at the University Hospital 12 de
Octubre, a 1300-bed hospital. A stewardship programme
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE MYCOLOGY
focusing on antibiotics had been previously developed in our
hospital [5]. The present study is an intervention study that
used a non-randomized uncontrolled before–after methodol-
ogy. The primary outcome of the study was a reduction in
antifungal expenditure. No stewardship programme targeting
antifungals existed in the hospital before the intervention.
The protocol of this study was approved by the Clinical
Investigation Ethics Committee. The study was supported by
the hospital administration. The study was led by the Infec-
tious Diseases Unit, and the Departments of Pharmacy,
Microbiology and Intensive Care actively cooperated in study
development. The intervention was developed in 2008–2009.
Programme description
The present programme was initiated in all departments of
the hospital attending to adults. A member of the Infectious
Diseases Unit (F.L.M.) was partially dedicated to this pro-
gramme (c. 3 h every weekday). All prescriptions of antifun-
gals were checked every working day. The following
prescriptions were selected to be reviewed: (i) every new
prescription; and (ii) prescriptions susceptible to modiﬁcation
or discontinuation according to the criteria of the investiga-
tor, taking into consideration the treatment indication. Anti-
fungal treatments were identiﬁed by the computerized
system of the Department of Pharmacy. The Infectious Dis-
eases Unit and the Department of Microbiology held a meet-
ing every day, at which every clinically relevant fungal isolate
was reported. Furthermore, the treatment of the patients
admitted to the Department of Haematology (22-bed ward),
the Postsurgical Unit of the Department of Anaesthesiology
(17-bed ward), and the Department of General Intensive
Care Medicine (14-bed ward) was reviewed. Throughout the
intervention period, every prescription of the following anti-
fungals was reviewed: intravenous liposomal amphotericin B,
intravenous caspofungin, and intravenous and oral voriconaz-
ole. The appropriateness of the antifungal treatment was
personally discussed with the attending physician. Most of
the cases resulted in oral recommendations. In cases where
the responsible physician could not be contacted, a written
recommendation could be left until personal contact could
be made. Recommendations were made regarding the neces-
sity for prescription of the antifungal drug, the route of
administration, the dose of the drug, and the possibility of
substitution with another antifungal drug. All of the recom-
mendations were non-compulsory. The attitude of the physi-
cian in charge concerning the recommendation was checked
48 h later. Recommendations were based on the guidelines
of the Infectious Diseases Society of America for the use of
antimicrobial agents in neutropenic patients [6], for the
treatment of intra-abdominal infections [7], and for diseases
caused by Aspergillus [8] and Candida [9]. Only local antimi-
crobial prescription guidelines were available in the Postsur-
gical Unit. A special effort was made to substitute
ﬂuconazole for caspofungin or liposomal amphotericin B
when ﬂuconazole-sensitive Candida species were isolated, to
stop the prescribed antifungal treatment when a Candida iso-
late was considered to be a colonizing organism (mainly iso-
lates from respiratory samples), to change from intravenous
to oral voriconazole when feasible, to stop empirical antifun-
gal treatment when the patient was considered to no longer
be at risk for this type of infection, and to stop prophylactic
antifungal treatment when the patient was considered to be
at low risk. The antifungal treatment of a single patient could
be reviewed more than once.
Description of outcomes
The results of the intervention were compared with the
results achieved in the hospital in the immediately preceding
12 months, which will be referred to hereafter as the pre-
intervention period. The deﬁned daily doses (DDDs) and anti-
fungal expenses were provided by the Department of Phar-
macy. A DDD of caspofungin was considered to be 50 mg,
and a DDD of oral or parenteral voriconazole was considered
to be 0.4 g [10]. As a DDD for liposomal amphotericin B has
not been described [10], the 50-mg vial was taken as the unit.
The expenses were based on the price paid by our hospital.
This price may differ from the ofﬁcially established price,
owing to discounts negotiated with antifungal drug suppliers.
All costs in Euros (Spanish currency) were converted to US
dollars, taking into consideration the equivalence at the end of
the intervention period (€1 = US$1.56). The antifungal expen-
ditures 2 years and 3 years before the intervention period
were also analysed. The Department of Microbiology provided
the information about the number of blood cultures positive
for Candida, and the percentage of Candida isolates resistant to
ﬂuconazole, during the intervention and the pre-intervention
periods. Susceptibility to ﬂuconazole was tested with a com-
mercially prepared dried colorimetric microdilution panel
(Sensititre YeastOne; Trek Diagnostic Systems Ltd., East Grin-
stead, UK). The yeast was considered to be susceptible when
the MIC of ﬂuconazole was £8 mg/L. Relapsing and persisting
candidaemia were analysed together for the purpose of this
study. The deﬁnition of this joint concept was the growth of
the same type of Candida species in a blood culture after 48 h
and within 30 days of the ﬁrst positive blood culture. Data on
the number of patients admitted to the hospital, in-hospital
mortality, average length of stay and number of days of hospi-
talization were provided by the administration of the hospital.
The following infections caused by ﬁlamentous fungi through-
out the intervention and the pre-intervention periods were
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identiﬁed in the computerized registry of the hospital accord-
ing to the standardized International Classiﬁcation of Diseases
(ICD-10) [11]: aspergillosis (B44), zygomycosis (B46), other
mycoses (B48), and unspeciﬁed mycosis (B49). Patients were
retrospectively diagnosed with invasive fungal diseases if they
could be included in the categories of probable or proven
infection [12]. A comparison of the incidence of candidaemia,
percentage of relapsing/persisting candidaemia, percentage of
candidaemia caused by ﬂuconazole-resistant yeasts, incidence
of infections caused by ﬁlamentous fungi and 12-month mor-
tality in patients diagnosed with ﬁlamentous fungi infection
throughout the intervention and the pre-intervention period
was used as a marker of the quality of the medical care
provided.
Statistical analysis
Continuous variables were expressed as the mean and stan-
dard deviation for those with a normal distribution. Categor-
ical variables were expressed as percentages. Student’s
unpaired t-test was used to compare continuous variables,
and the chi-square or Fisher exact test was applied to com-
pare proportions when appropriate. All statistical tests were
two-tailed. A p-value of <0.05 was considered to be statisti-
cally signiﬁcant.
Results
Throughout the intervention period, a total of 5291 days on
antifungal treatment were detected (Table 1), and 662 treat-
ments were considered to be susceptible for review. The
Intensive Care and Postsurgical Units were the departments
with the highest number of reviewed treatments (38.7%). In
>50% of the cases, treatments were active in targeting Can-
dida species, followed by treatments targeting Aspergillus;
both fungi were the target of >90% of the prescriptions. The
most frequent indication for the drugs was the treatment of
conﬁrmed infections (Table 1). In 71% of the cases, the pre-
scription made by the treating physician was considered to
be correct. For 29% of the treatments, the following recom-
mendations were made: in 15% of cases, the recommenda-
tion was to change from intravenous to oral treatment; in
8% of cases, the recommendation was to stop the adminis-
tration of the antifungal; and in 6% of cases, the recommen-
dation was to substitute ﬂuconazole for the prescribed
antifungal. In only 1% of the cases was the recommendation
not accepted (three in the Intensive Care Unit, two in the
Haematology Unit, and two in the Internal Medicine Unit). A
mean of 4.5 revisions per patient was made in patients with
conﬁrmed infections.
Throughout the pre-intervention and the intervention
periods, there were only slight changes in the mean price
paid by the hospital for the different antifungals (Table 2);
the price of a DDD of intravenous voriconazole and the
price of a 50-mg vial of liposomal amphotericin B were
the same in both periods. There was a reduction in the
price of a DDD of caspofungin during the intervention
period (0.11% reduction, equivalent to US$0.83 per dis-
pensed DDD). There was a 3.39% increase in the mean
price of oral voriconazole (US$3.79 per consumed DDD).
The differences in the numbers of prescribed DDDs or
vials of antifungals were analysed (Table 2), and important
reductions in the prescribed doses of intravenous vorico-
nazole and caspofungin were noted (31.4% and 20.2%
reduction, respectively). In contrast, there was a 13.9%
increase in the number of dispensed vials of liposomal
amphotericin B and a 8.2% increase in the number of dis-
penses doses of oral voriconazole. Global expenditure on
the four types of antifungal drug was US$3129387.34 in
the pre-intervention period, in contrast to US$2758705.56
in the intervention period, resulting in a global reduction
in antifungal costs of 11.84% and a cost saving of
US$370681.78.
Fungal infections were examined to verify the quality of
care provided (Table 3). The numbers of episodes of candi-
daemia were 69 in the pre-intervention period and 52 in the
intervention period. There was no increase in the percentage
TABLE 1. Characteristics of reviewed antifungal treatments
in the intervention period
N (%)
Reviewed antifungal treatments 662 (100)
Hospital department
Intensive Care and Reanimation Units 256 (38.7)
Haematology and Oncology 188 (28.4)
Surgical Departments 128 (19.3)
Medical Departments 90 (13.6)
Days on treatment with antifungals
Voriconazole (IV) 458
Voriconazole (oral) 2152
Caspofungin 1815
Liposomal amphotericin B 866
Total number of days on antifungals 5291
Target of prescribed antifungal treatment
Candida 342 (51.7)
Aspergillus 285 (43)
Zygomycosis 15 (2.3)
Others 20 (3)
Indication for an antifungal drug
Prophylaxis 181 (27.3)
Empirical treatment 201 (30.4)
Treatment of conﬁrmed infection 280 (42.3)
Type of recommendation
Treatment considered correct 470 (71)
Change IV to oral treatment 99 (15)
Cessation of treatment 53 (8)
Change to ﬂuconazole 40 (6)
Recommendation not accepted 7 (1)
IV, intravenous.
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of persisting or relapsing episodes of candidaemia. There was
no increase in the percentage of episodes of candidaemia
caused by ﬂuconazole-resistant species. Candida albicans was
the species most frequently isolated in blood cultures in both
periods, followed by Candida parapsilosis (Table 3). The num-
ber of episodes of infection by ﬁlamentous fungi was 18 dur-
ing the pre-intervention period, including ten episodes of
aspergillosis, two episodes of pulmonary aspergillomas, ﬁve
episodes of zygomycosis, and one episode of infection by Cla-
dosporium macrocarpum. The number of ﬁlamentous fungal
infections was ten during the intervention period, including
eight episodes of aspergillosis, one episode of zygomycosis,
and one episode of scedosporiosis. The difference was not
signiﬁcant (Table 3).
There was a 13.7% increase in expenditure between the
third year before and the second year before the interven-
tion periods (from US$2 300 288 to US$2 614 538). There
was a 19.7% increase in expenditure between the second
year before the pre-intervention period and the pre-inter-
vention period itself (US$2 614 538 to US$3 129 387). In
contrast, this trend was reversed by an 11.8% reduction in
expenditure between the pre-intervention period and the
intervention period (Table 3; Fig. 1).
Discussion
The appropriate use of antimicrobials has the potential to
improve efﬁcacy, reduce treatment-related costs, minimize
drug-related adverse events, and limit the potential for emer-
gence of antimicrobial resistance [13]. Recently published
guidelines on antimicrobial stewardship programmes have
raised the importance of having an infectious diseases spe-
cialist as a core member of the team [14].
Most decisions on antifungal prescriptions are made by phy-
sicians who are experts in their own ﬁeld, but who do not nec-
essarily have the expertise required to make informed choices
in the prescription of antifungals. More than half of the pre-
scriptions were made in the Departments of Haematology,
Oncology and Intensive Care. In cases where a stewardship
programme cannot be developed for the whole hospital, these
departments should be the preferred targets.
TABLE 2. Comparison of dispensed antifungals and their cost between the pre-intervention and intervention periods
Mean cost of an individual DDDa (US$) Dispensed DDD per 105 days of hospitaliza-
tiona
Cost of antifungal treatment (US$)
Pre-intervention
period
Intervention
period
Change
between
periods (%)
Pre-intervention
period
Intervention
period
Change
between
periods (%)
Pre-intervention
period
Intervention
period
Change
between
periods (%)
Voriconazole (IV) 432.9 432.9 0 246.14 168.77 ) 31.4 331 210.11 224 239.08 ) 32.3
Voriconazole (oral) 111.96 115.75 + 3.39 666.66 721.82 + 8.2 231 997.3 256 460.88 + 10.5
Caspofungin 728.88 728.05 ) 0.11 822.70 656.82 ) 20.2 1 863 765.88 1 467 699.48 ) 21.2
Liposomal
amphotericin B
187.11 187.11 0 1238.72 1411.06 + 13.9 702 414.05 810 306.12 + 12.5
Global 3 129 387.34 2 758 705.56 ) 11.8
Global saving: US$370 681.78
DDD, deﬁned daily dose; IV, intravenous.
aDispensed in 50-mg vials in the case of liposomal amphotericin B.
TABLE 3. Comparison of fungal infections between the pre-intervention and intervention periods
Pre-intervention period Intervention period p
Patients admitted to the hospital 26 996 26 991
Total number of days of hospitalization 310 803 306 932
Episodes of candidaemia 69 52
Episodes of candidaemia per 103 hospital admissions 2.55 1.93 NS
Episodes of candidaemia per 104 days of hospitalization 2.22 1.92 NS
Candida albicans, n (%) 31 (45) 20 (38) NS
Candida parapsilosis, n (%) 21 (30) 19 (36) NS
Candida glabrata, n (%) 10 (13) 12 (23) NS
Candida tropicalis, n (%) 5 (7.5) 1 (2) NS
Candida krusei, n (%) 2 (3) 0 (0) NS
Episodes of relapsing/persisting candidemia, n (%) 16 (24) 10 (19) NS
% of candidaemia caused by ﬂuconazole-resistant Candida species 4.7 5.3 NS
Episodes of ﬁlamentous fungal infections 18 10
Episodes of ﬁlamentous fungal infections per 103 hospital admissions 0.67 0.37 NS
Episodes of ﬁlamentous fungal infections per 104 days of hospitalization 0.58 0.32 NS
12-month mortality in patients with the diagnosis of ﬁlamentous fungal infection, n (%) 9 (50) 5 (50) NS
NS, not signiﬁcant.
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An acceptance of recommendations by physicians in
charge of the patients can be challenging if there is a per-
ceived loss of autonomy in clinical decision-making [13]. One
of the strengths of our programme was that the recommen-
dations were voluntary rather than mandatory. One of the
reasons for the success of our programme was that the rec-
ommendations were personally made to the physician in
charge. It is plausible that the effect of the programme
extended beyond the controlled treatments; the reduction in
prescriptions could be explained, in part, by the spontaneous
initiative of treating physicians in the restriction of antifungals
as part of the ‘pleiotropic’ effect of the programme. There
was a progressive increase in antifungal expenditure in the
years preceding the intervention. With the developed pro-
gramme, this trend was not only stopped, but also reversed
(Fig. 1). As the only cost of the programme was the part-
time workday dedicated by the main investigator, its devel-
opment was cost-effective.
During the intervention period, there was a reduction in
the prescription of intravenous voriconazole that could, in
part, be explained by a change in the prescription from intra-
venous to oral treatment. This change is reasonable, and
takes into consideration the excellent oral bioavailability of
this drug [15]. Part of the counterbalance of this reduction
was an increase in the prescription of oral voriconazole. The
main component of the cost savings was the important
reduction in the use of caspofungin. It is probable that this
drug was used in a more restrictive way for empirical treat-
ment or prophylaxis in patients with a low risk of Candida
infection. There was an increase in the prescription of lipo-
somal amphotericin B. As neutropenia episodes were not
systematically monitored, a higher number of episodes during
the intervention period in which the drug was used cannot
be ruled out.
The quality of care provided must be an essential part of
any antimicrobial stewardship programme. There was no
change in the incidence of mould or yeast infections, and
there was no change in disease prognosis.
Previous studies have found misuse of antifungals in 26.9%
[16] and 74% [17] of cases. To the best of our knowledge,
there is only one previous report of a stewardship pro-
gramme targeting antifungals active against Candida [4]. The
authors concluded that there was a reduction in the inap-
propriate use of antifungals against Candida from 71% to
24%. There is no previously reported experience on stew-
ardship programmes targeting antifungals against ﬁlamentous
fungi.
There are some limitations to our study that should be
noted. The results obtained in the intervention period were
compared with those of the previous 12 months; thus, a bias
resulting from a change in the characteristics of the admitted
patients cannot be ruled out. This is an intrinsic limitation of
studies with this type of design. Another limitation is that
the programme was restricted to speciﬁc types of antifun-
gals. When the study was developed, the only equinocandin
available in our hospital was caspofungin, and posaconazole
was not in the formulary. Adverse effects of antifungals were
not speciﬁcally assessed. It is reasonable to suppose that the
reduction in the prescription of antifungals was accompanied
by a reduction in adverse effects. The rate of re-admission
was not assessed.
Hospitals interested in developing a similar programme
should pay special attention to the assignment of an expert
in fungal infections, generate tight relationships with depart-
ments using these drugs, perform an exhaustive search of
prescriptions on antifungals, prepare for the delivery of
personal recommendations about speciﬁc patients, and
allow close feedback. Future studies should explore the
possibility of developing antifungal stewardship programmes
more easily, and maintaining them for extended periods of
time.
In conclusion, in the present environment of complexity in
the prescription of antifungals, the development of steward-
ship programmes for these drugs could be of key importance
in optimizing antifungal use while reducing expenditure and
without detrimentally affecting the quality of care provided.
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